When I first initiated coverage on Carasent, my core thesis was straightforward. I saw a high-margin, critical healthcare software engine trapped in the turmoil of an aggressive 2020–2022 acquisition spree. It was a operator-led turnaround ready to unlock operating leverage.
Across the prior memos; from the profitability inflection in Q3 2025 to buying the AI disintermediation panic in Q4 2025 and tracking the core acceleration in Q1 2026, the original thesis still held fast.
What I believe the market currently is missing is that Carasent has become a highly profitable, multi-vector expansion platform.
The integration of InfoSolutions is creating high-margin diagnostic transaction flows.
Medsum AI documentation assistant has moved from pilot status to a commercial add-on driving organic average revenue per user (ARPU).
The German expansion via the localized Webcur platform (formerly Webdoc X) has achieved its critical initial milestone by onboarding its first paying customers.
Trading at SEK 24.70, the market continues to price Carasent at a disconnect from its underlying cash generation potential.
Snapshot: Carasent AB (publ)
Ticker: CARA.ST (Nasdaq Stockholm)
Share Price: SEK 24.70 (5th of August 2026)
Market Cap: ~SEK 1.7 billion
Enterprise Value (EV): ~SEK 1.55 billion
Net Cash: SEK 140 million
Sector: Healthcare Vertical SaaS
5-year outlook: High-conviction BUY with a Base Case target of SEK 77 (+25.5% CAGR next 5 years)
